-
Product Insights
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Drugs In Development, 2024
Empower your strategies with our Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Drugs In Development, 2024 report and make more profitable business decisions. Hereditary angioedema (HAE) is a rare inherited disease that causes considerable swelling in various body tissues, such as the abdomen or face. Symptoms include severe abdominal pain and cramping, dehydration, diarrhea and shock, hoarse voice, difficulty swallowing,and difficulty breathing. Treatment includes medications such as epinephrine, antihistamines, and corticosteroids. The Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH]...
-
Product Insights
Pollen Allergy - Drugs In Development, 2024
Empower your strategies with our Pollen Allergy – Drugs In Development, 2024 report and make more profitable business decisions. Pollen allergy, characterized by sensitivity to the minute particles released seasonally by trees, grasses, and weeds, occurs when these pollen grains disperse through the air in their journey to fertilize plants. The particles frequently infiltrate noses, eyes, ears, and mouths, instigating the onset of allergy symptoms. Sneezing, nasal congestion, and itchy eyes are common manifestations of the immune system's response to these...
-
Product Insights
Cytokine Release Syndrome (Cytokine Storm) - Drugs In Development, 2024
Empower your strategies with our Cytokine Release Syndrome (Cytokine Storm) – Drugs In Development, 2024 report and make more profitable business decisions. Cytokine release syndrome (CRS) is a systemic inflammatory response, potentially life-threatening and triggered by various factors like infections and specific drugs. It can occur following the administration of natural and bispecific antibodies, as well as adoptive T-cell therapies for cancer. CRS is characterized by elevated levels of cytokines, including interleukin (IL)-6 and interferon γ. Tocilizumab, an anti-IL-6 receptor antibody,...
-
Product Insights
Cutaneous Lupus Erythematosus - Drugs In Development, 2024
Empower your strategies with our Cutaneous Lupus Erythematosus – Drugs In Development, 2024 report and make more profitable business decisions. Cutaneous lupus erythematosus (CLE) is lupus affecting the skin. It is a diverse group of autoimmune connective tissue disorders localised to the skin that can be associated with systemic lupus erythematosus (SLE) to varying degrees. Cutaneous lupus erythematosus (CLE) is classified as Acute (ACLE), Subacute (SCLE), Intermittent (lupus tumidus) and chronic (CCLE) eg, discoid lupus (DLE), lupus profundus, chilblain lupus erythematosus....
-
Product Insights
Hematopoietic Stem Cell Transplantation - Drugs In Development, 2024
Empower your strategies with our Hematopoietic Stem Cell Transplantation – Drugs In Development, 2024 report and make more profitable business decisions. Hematopoietic stem-cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived from bone marrow, peripheral blood, or umbilical cord blood in order to replicate inside of a patient and to produce additional normal blood cells. It may be autologous (the patient's own stem cells are used), allogeneic (the stem cells come from a donor) or syngeneic (from...
-
Product Insights
Pemphigus - Drugs In Development, 2024
Empower your strategies with our Pemphigus – Drugs In Development, 2024 report and make more profitable business decisions. Pemphigus is is an autoimmune disease that causes blistering of the skin and the the mucous membranes inside of the mouth, nose, throat, eyes, and genitals. It is characterized by loss of normal cell-cell adhesion (acantholysis) and by the presence of pathogenic (predominantly IgG) autoantibodies reacting against epithelial adhesion molecules called desmogleins, proteins that bind skin cells to one another. When these bonds...
-
Product Insights
Sarcoidosis - Drugs In Development, 2024
Empower your strategies with our Sarcoidosis – Drugs In Development, 2024 report and make more profitable business decisions. Sarcoidosis is a systemic inflammatory disease that can affect any organ. It is characterized by the development and growth of tiny lumps of cells called granulomas. The disease usually begins in the lungs, skin, or lymph nodes. The cause of sarcoidosis is unknown. Signs and symptoms of sarcoidosis vary based on the location of the granulomas and the severity of the condition. The...
-
Product Insights
Anaphylaxis - Drugs In Development, 2024
Empower your strategies with our Anaphylaxis – Drugs In Development, 2024 report and make more profitable business decisions. Anaphylaxis is a severe, potentially life-threatening allergic reaction. Anaphylaxis symptoms include dizziness, nausea, vomiting or diarrhea, feeling of warmth, constriction of the airways, and a swollen tongue or throat. Risk factors include personal history of anaphylaxis, allergies or asthma, and family history. Treatment includes beta-agonists, antihistamines, and cortisone. The Anaphylaxis drugs in development market research report provide comprehensive information on the therapeutics under...
-
Product Insights
Generalized Pustular Psoriasis (GPP) - Drugs In Development, 2024
Empower your strategies with our Generalized Pustular Psoriasis (GPP) – Drugs In Development, 2024 report and make more profitable business decisions. Pustular psoriasis is a rare and extreme form of psoriasis characterized by the appearance of sterile pustules which can take many patterns. All the main pathological features of the disease are accentuated. Generalized pustular psoriasis is clinically heterogeneous in its age at onset, precipitants, severity, and natural history. Generalized pustular psoriasis is often associated with metabolic syndrome and polyarthritis The...
-
Product Insights
Birch Pollen Allergy - Drugs In Development, 2024
Empower your strategies with our Birch Pollen Allergy – Drugs In Development, 2024 report and make more profitable business decisions. Birch pollen allergy is a reaction which occurs soon after exposure to the pollen of birch trees. Signs and symptoms include skin reactions, such as hives, redness, or swelling; itching or tingling in or around the mouth and throat; digestive problems such as diarrhea, stomach cramps, nausea, or vomiting; tightening of the throat; shortness of breath or wheezing; and runny nose....
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.